Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
November 2023
in “
Clinical Pharmacokinetics
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
Studysummary This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer